RA
TLSI icon

Royce & Associates’s TriSalus Life Sciences TLSI Stock Holding History

Royce & Associates’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Hold
200,060
– – 0.01% 684
2026
Q1 		$800K Buy
+200,060
New +$980K 0.01% 667

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Royce & Associates's TLSI Position: Q2 2026 in Review

Royce & Associates held its TriSalus Life Sciences (TLSI) position steady in Q2 2026 at 200,060 shares worth $910K. The position accounts for 0.01% of the portfolio, ranked #684.

Royce & Associates first reported a position in TLSI in Q1 2026 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Royce & Associates held 200,060 shares of TriSalus Life Sciences worth $910K as of Q2 2026.
  • Royce & Associates left its TriSalus Life Sciences share count unchanged in Q2 2026.
  • TriSalus Life Sciences made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #684 holding.
  • Royce & Associates first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.